Overview

A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer

Status:
Recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

The study is being conducted to assess the efficacy and safety of anthracycline-containing ddEC-THP intensive regimen and an anthracycline-free TCbHP neoadjuvant therapy for HER2-positive breast cancer

Phase:

Phase 3

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital